In fact, the pooled OS data for stage IB-IIIA NSCLC patients in the present meta-analysis also indicated a strong OS benefit from osimertinib adjuvant treatment (Fig. 3A), thus strengthening the evidence for the efficacy of adjuvant osimertinib treatment in terms of OS in patients with EGFR-mutant NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.